Patents by Inventor Nir Hacohen

Nir Hacohen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240150711
    Abstract: The disclosure provides methods of reprogramming polyclonal T cells to maintain long-term persistence. The disclosure further provides methods of treatment, such as adoptive T cell transfer therapies, that harness Tscms for development of tumor-reactive T cells. In some embodiments, the disclosure provides methods and compositions for positive modulation of the Tscm-producing phenotype, e.g., positive modulation of TCF7 expression. Positive modulation of TCF7 expression allows for maintenance of an increased T number of stem-like T cells capable of both self-renewal and generation of differentiated, cytolytic progeny.
    Type: Application
    Filed: March 1, 2022
    Publication date: May 9, 2024
    Applicants: Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Marc Schwartz, Nir Hacohen
  • Patent number: 11965892
    Abstract: Systems, compositions, and methods for isolating HLA-peptides from cells. A universal platform and methods for profiling the HLA-peptidome, enabling identification of endogenously presented HLA-peptides from cell lines expressing any possible class I or II construct.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: April 23, 2024
    Assignee: BioNTech US Inc.
    Inventors: Jennifer Grace Abelin, Rob Carl Oslund, Nir Hacohen, Dominik Barthelme, Michael Rooney
  • Publication number: 20240124924
    Abstract: The present disclosure relates to methods and compositions for enhanced assessment of exogenous polynucleotide and/or polypeptide-mediated transcriptional perturbations at high throughput and single cell/droplet levels of resolution. In embodiments, nucleic acid fusions of exogenous polynucleotide(s) and associated target transcript(s) are produced within individually sequestered or discretely identifiable cells/lysates and analyzed for exogenous polynucleotide mediated perturbations across a vast population of droplets/cells within individual reactions. Kits for performance of the methods are also provided.
    Type: Application
    Filed: February 22, 2022
    Publication date: April 18, 2024
    Applicants: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE GENERAL HOSPITAL CORPORATION
    Inventors: Aziz Al'Khafaji, Frances Keer, Paul Blainey, Nir Hacohen
  • Patent number: 11939637
    Abstract: In one aspect, provided herein is a method comprising: (a) (i) determining cytolytic activity in a tumor from the subject; and/or (ii) determining genetic alterations associated with cytolytic activity in the tumor; and (b) administering an immunotherapeutic agent to the subject if (i) cytolytic activity is detected in the tumor and/or (ii) a genetic alteration associated with induction of cytolytic activity, tumor resistance to cytolytic activity and/or suppression of cytolytic activity is detected in the tumor.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: March 26, 2024
    Assignees: Massachusetts Institute of Technology, The General Hospital Corporation
    Inventors: Nir Hacohen, Michael S. Rooney
  • Publication number: 20230407397
    Abstract: The present disclosure provides methods for determining signatures of immune responses to immunomodulating agents in cells and in tissues. Also provided herein are computational methods for deconvoluting gene expression profiling data. Further provided herein are methods for treating a disease or disorder (e.g, proliferative diseases such as cancer, autoimmune diseases such as rheumatoid arthritis and psoriasis, allergies, etc.) in a subject comprising administering one or more immunomodulating agents to drive an immune response, in combination with a treatment for the disease or disorder (e.g, an anti-cancer therapy, an anti-viral therapy, a vaccination, etc.).
    Type: Application
    Filed: November 4, 2021
    Publication date: December 21, 2023
    Applicants: Massachusetts Institute of Technology, The General Hospital Corporation
    Inventors: Nir Hacohen, Ang Cui
  • Publication number: 20230384320
    Abstract: Compositions and methods for isolating HLA-peptides from cells. A universal platform and methods for profiling the HLA-peptidome, enabling identification of endogenously presented HLA-peptides from cell lines expressing any possible class I or II construct.
    Type: Application
    Filed: March 28, 2023
    Publication date: November 30, 2023
    Inventors: Jennifer Grace Abelin, Rob Carl Oslund, Nir Hacohen, Dominik Barthelme, Michael Rooney
  • Publication number: 20230383298
    Abstract: The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shRNA, immunoresponsive cells expressing shRNA and/or a chimeric antigen receptors (CAR)), and methods of use thereof.
    Type: Application
    Filed: January 3, 2023
    Publication date: November 30, 2023
    Applicants: Dana-Farber Cancer Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Kai W. Wucherpfennig, Glenn Dranoff, Penghui Zhou, Donald Shaffer, Nir Hacohen, Harvey I. Cantor, Diana Alvarez Arias
  • Patent number: 11766446
    Abstract: Provided herein, in some embodiments, are methods for treating age-associated conditions, including systemic inflammation and disease, via enhanced DNA degradation.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: September 26, 2023
    Assignee: The General Hospital Corporation
    Inventors: Yuk Yuen Lan, Nir Hacohen
  • Publication number: 20230235394
    Abstract: The present disclosure relates to compositions and methods for nucleic acid sequencing, and specifically, at least in certain aspects, provides methods and compositions for enhancing the efficacy, throughput and/or yield of known long-range sequencing platforms, by providing chimeric arrays of input sequences. Such arrays of component nucleic acid sequence elements can be prepared via methods that minimize introduction of bias. The application of the current methods to obtain isoform sequencing information, e.g., from patient samples is specifically also provided, as are methods for mitochondrial lineage tracing that employ the instant chimeric amplicon sequencing processes. Methods and systems for array nucleic acid sequence processing and interpretation are also provided.
    Type: Application
    Filed: June 14, 2021
    Publication date: July 27, 2023
    Inventors: Nir HACOHEN, Aziz AL'KHAFAJI, Paul BLAINEY, Mehrtash BABADI, Kiran V GARIMELLA, Jonathan Theodore SMITH
  • Publication number: 20230193356
    Abstract: The present disclosure relates to compositions and methods for single-cell nucleic acid sequencing, and specifically provides for pre-amplifying target nucleic acids in a manner that allows for more proportionate detection of all target nucleic acids, including low prevalence/abundance RNAs, from individual cells. The disclosure also provides for application of a series of barcoding steps to associate cell-specific identifiers (IDs) to the targeted nucleotide sequences, and ultimately provides for increased throughput capacity and greater accuracy of single-cell nucleic acid sequencing. Certain aspects of the present disclosure also provide for improved quantitative detection of nucleic acid sequence barcodes, which in embodiments allows for highly sensitive quantitative detection of barcoded antibody levels and/or highly sensitive quantitative detection of barcoded antibody-bound protein levels (e.g.
    Type: Application
    Filed: June 7, 2021
    Publication date: June 22, 2023
    Applicants: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE GENERAL HOSPITAL CORPORATION
    Inventors: Aziz Al'Khafaji, Paul Blainey, Nir Hacohen
  • Publication number: 20230190896
    Abstract: The present invention relates to neoplasia vaccine or immunogenic composition administered in combination with other agents, such as checkpoint blockade inhibitors for the treatment or prevention of neoplasia in a subject.
    Type: Application
    Filed: July 29, 2022
    Publication date: June 22, 2023
    Inventors: Nir Hacohen, Catherine Ju-Ying Wu, Edward F. Fritsch
  • Patent number: 11650211
    Abstract: Compositions and methods for isolating HLA-peptides from cells. A universal platform and methods for profiling the HLA-peptidome, enabling identification of endogenously presented HLA-peptides from cell lines expressing any possible class I or II construct.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: May 16, 2023
    Assignee: BioNTech US INC.
    Inventors: Jennifer Grace Abelin, Rob Carl Oslund, Nir Hacohen, Dominik Barthelme, Michael Rooney
  • Patent number: 11634777
    Abstract: Provided herein are methods of determining resistance to checkpoint blockade (CPB) therapy in a cancer patient, methods of typing tumor cells of a cancer patient, methods of assigning treatment to a cancer patient and methods of treatment of a cancer patient based on determining in a tumor sample of said patient, reduced expression of a gene relating to antigen processing pathway or a product thereof, or a modification causing said reduced expression, wherein the presence of said reduced expression or modification is indicative of resistance to CPB therapy.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: April 25, 2023
    Assignee: The General Hospital Corporation
    Inventors: Nir Hacohen, Moshe Sade-Feldman
  • Patent number: 11630103
    Abstract: The present invention provides isolated immune cells, immune cell populations and compositions, as well as markers, marker signatures and molecular targets characterising the immune cells. The cell products, substances, compositions, markers, marker signatures, molecular targets, kits of parts and methods of the present invention provide for new ways to characterise, evaluate and modulate the immune system and immune responses.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: April 18, 2023
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, The General Hospital Corporation
    Inventors: Alexandra-ChloƩ Villani, Rahul Satija, Aviv Regev, Nir Hacohen
  • Patent number: 11597934
    Abstract: The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shRNA, immunoresponsive cells expressing shRNA and/or a chimeric antigen receptors (CAR)), and methods of use thereof.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: March 7, 2023
    Assignees: DANA FARBER CANCER INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATION
    Inventors: Kai W. Wucherpfennig, Glenn Dranoff, Penghui Zhou, Donald Shaffer, Nir Hacohen, Harvey I. Cantor, Diana Alvarez Arias
  • Publication number: 20220397568
    Abstract: The present invention provides isolated immune cells, immune cell populations and compositions, as well as markers, marker signatures and molecular targets characterising the immune cells. The cell products, substances, compositions, markers, marker signatures, molecular targets, kits of parts and methods of the present invention provide for new ways to characterise, evaluate and modulate the immune system and immune responses.
    Type: Application
    Filed: August 17, 2017
    Publication date: December 15, 2022
    Inventors: Alexandra-ChloƩ VILLANI, Rahul SATIJA, Aviv Regev, Nir HACOHEN
  • Patent number: 11452768
    Abstract: The present invention relates to neoplasia vaccine or immunogenic composition administered in combination with other agents, such as checkpoint blockade inhibitors for the treatment or prevention of neoplasia in a subject.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: September 27, 2022
    Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Nir Hacohen, Catherine J. Wu, Edward F. Fritsch
  • Publication number: 20220299511
    Abstract: Provided herein, in some embodiments, are methods for analyzing immune cells in a blood sample from a subject having, suspected of having, or being at risk for bacterial sepsis. The present disclosure is based, at least in part, on the finding that certain immune cells are expanded in subjects having sepsis compared to healthy subjects.
    Type: Application
    Filed: June 17, 2020
    Publication date: September 22, 2022
    Applicants: The Broad Institute, Inc., Massachusetts Institute of Technology, The General Hospital Corporation
    Inventors: Miguel Reyes, Nir Hacohen, Paul C. Blainey, Michael R. Filbin, Marcia B. Goldberg, Roby P. Bhattacharyya
  • Publication number: 20220282333
    Abstract: The present invention provides methods of predicting a patient's response to immunotherapy, in particular checkpoint blockade therapy, and provides for treatments. Disclosed herein are novel combinations of factors identified in tumors used to predict response and provide for treatments. Also, disclosed are methods of treatment that can shift a tumor to a responder phenotype.
    Type: Application
    Filed: August 13, 2020
    Publication date: September 8, 2022
    Inventors: Samuel Freeman, Moshe Sade-Feldman, Nir Hacohen, Gad Getz, Matthew Meyerson
  • Publication number: 20220088180
    Abstract: Immunogenic compositions comprising one or more polypeptides, wherein the one or more polypeptides: is capable of binding to Major Histocompatibility Complex (MHC) class I, and is derived from one or more proteins of SARS-CoV-2. Also provided include methods of treating and preventing diseases using the immunogenic compositions.
    Type: Application
    Filed: August 31, 2021
    Publication date: March 24, 2022
    Inventors: Pardis SABETI, Shira Weingarten-Gabbay, Susan Klaeger, Jenn Abelin, Mohsan Saeed, Nir Hacohen, Siranush Sarkizova, Steven Carr, Karl Clauser